1
|
Hall J, Ashkinadze A, Becker JP, Laski A, Manz EM, Moravčík Š, Sjöström S, Vincent M. Medicinal Chemistry of Oligonucleotide Drugs - Milestones of the Past and Visions for the Future. Chimia (Aarau) 2022. [DOI: 10.2533/chimia.2022.466] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
The oligonucleotide therapeutics field has blossomed in recent years, with thirteen approved drugs today and the promise of accelerated growth in coming years. Much of the progress in this field is due to advances in the medicinal chemistry of oligonucleotides,combined with a judicious choice of molecular targets and disease areas. In this perspective, we describe the growth of this new class of drugs highlighting selected milestones in oligonucleotide medicinal chemistry.
Collapse
|
2
|
Nikitidis G, Carlsson ACC, Karlsson S, Campbell AD, Cook C, Dai K, Emtenäs H, Jonson AC, Leek H, Malmgren M, Moravčík Š, Pithani S, Tatton MR, Zhao H, Öhlén K. Synthetic and Chromatographic Challenges and Strategies for Multigram Manufacture of KRASG12C Inhibitors. Org Process Res Dev 2021. [DOI: 10.1021/acs.oprd.1c00179] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Affiliation(s)
- Grigorios Nikitidis
- Early Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca Gothenburg, SE-431 83 Mölndal, Sweden
| | - Anna-Carin C. Carlsson
- Early Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca Gothenburg, SE-431 83 Mölndal, Sweden
| | - Staffan Karlsson
- Early Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca Gothenburg, SE-431 83 Mölndal, Sweden
| | - Andrew D. Campbell
- Chemical Development, Pharmaceutical Technology & Development, Operations, AstraZeneca Macclesfield, Macclesfield SK10 2NA, United Kingdom
| | - Calum Cook
- Early Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca Macclesfield, Macclesfield SK10 2NA, United Kingdom
| | - Kuangchu Dai
- Changzhou SynTheAll Pharmaceutical Co., Ltd, No 589, North Yulong Road, Chunjiang town, Xinbei District, Changzhou 213127, Jiangsu, China
| | - Hans Emtenäs
- Early Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca Gothenburg, SE-431 83 Mölndal, Sweden
| | - Anna C. Jonson
- Early Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca Gothenburg, SE-431 83 Mölndal, Sweden
| | - Hanna Leek
- Early Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca Gothenburg, SE-431 83 Mölndal, Sweden
| | - Marcus Malmgren
- Early Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca Gothenburg, SE-431 83 Mölndal, Sweden
| | - Štefan Moravčík
- Early Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca Gothenburg, SE-431 83 Mölndal, Sweden
| | - Subhash Pithani
- Early Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca Gothenburg, SE-431 83 Mölndal, Sweden
| | - Matthew R. Tatton
- Early Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca Macclesfield, Macclesfield SK10 2NA, United Kingdom
| | - Hucheng Zhao
- Changzhou SynTheAll Pharmaceutical Co., Ltd, No 589, North Yulong Road, Chunjiang town, Xinbei District, Changzhou 213127, Jiangsu, China
| | - Kristina Öhlén
- Early Chemical Development, Pharmaceutical Sciences, Biopharmaceuticals R&D, AstraZeneca Gothenburg, SE-431 83 Mölndal, Sweden
| |
Collapse
|
3
|
Abstract
The direct reduction of carboxylic acids to aldehydes is a fundamental transformation in organic synthesis. The combination of an air-stable Ni precatalyst, dimethyl dicarbonate as an activator, and silane reductant effects this reduction for a wide variety of substrates, including pharmaceutically relevant structures, in good yields and with no overreduction to alcohols. Moreover, this methodology is scalable, allows access to deuterated aldehydes, and is also compatible with one-pot utilization of the aldehyde products.
Collapse
Affiliation(s)
- Andrei V Iosub
- Medicinal Chemistry, Research and Early Development Cardiovascular, Renal and Metabolism , BioPharmaceuticals R&D, AstraZeneca , Gothenburg , Sweden
| | - Štefan Moravčík
- Medicinal Chemistry, Research and Early Development Cardiovascular, Renal and Metabolism , BioPharmaceuticals R&D, AstraZeneca , Gothenburg , Sweden
| | - Carl-Johan Wallentin
- Department of Chemistry and Molecular Biology , Gothenburg University , Gothenburg , Sweden
| | - Joakim Bergman
- Medicinal Chemistry, Research and Early Development Cardiovascular, Renal and Metabolism , BioPharmaceuticals R&D, AstraZeneca , Gothenburg , Sweden
| |
Collapse
|
4
|
Littleson MM, Campbell AD, Clarke A, Dow M, Ensor G, Evans MC, Herring A, Jackson BA, Jackson LV, Karlsson S, Klauber DJ, Legg DH, Leslie KW, Moravčík Š, Parsons CD, Ronson TO, Meadows RE. Synthetic Route Design of AZD4635, an A2AR Antagonist. Org Process Res Dev 2019. [DOI: 10.1021/acs.oprd.9b00171] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Mairi M. Littleson
- Chemical Development, Pharmaceutical Technology and Development, AstraZeneca, Macclesfield Campus, SK10 2NA, Macclesfield, U.K
| | - Andrew D. Campbell
- Chemical Development, Pharmaceutical Technology and Development, AstraZeneca, Macclesfield Campus, SK10 2NA, Macclesfield, U.K
| | - Adam Clarke
- Chemical Development, Pharmaceutical Technology and Development, AstraZeneca, Macclesfield Campus, SK10 2NA, Macclesfield, U.K
| | - Mark Dow
- Chemical Development, Pharmaceutical Technology and Development, AstraZeneca, Macclesfield Campus, SK10 2NA, Macclesfield, U.K
| | - Gareth Ensor
- Chemical Development, Pharmaceutical Technology and Development, AstraZeneca, Macclesfield Campus, SK10 2NA, Macclesfield, U.K
| | - Matthew C. Evans
- Chemical Development, Pharmaceutical Technology and Development, AstraZeneca, Macclesfield Campus, SK10 2NA, Macclesfield, U.K
| | - Adam Herring
- Chemical Development, Pharmaceutical Technology and Development, AstraZeneca, Macclesfield Campus, SK10 2NA, Macclesfield, U.K
| | - Bethany A. Jackson
- Chemical Development, Pharmaceutical Technology and Development, AstraZeneca, Macclesfield Campus, SK10 2NA, Macclesfield, U.K
| | - Lucinda V. Jackson
- Chemical Development, Pharmaceutical Technology and Development, AstraZeneca, Macclesfield Campus, SK10 2NA, Macclesfield, U.K
| | - Staffan Karlsson
- Early Chemical Development, Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, SE-431 83 Mölndal, Sweden
| | - David J. Klauber
- Chemical Development, Pharmaceutical Technology and Development, AstraZeneca, Macclesfield Campus, SK10 2NA, Macclesfield, U.K
| | - Danny H. Legg
- Early Chemical Development, Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, Macclesfield Campus, SK10 2NA, Macclesfield, U.K
| | - Kevin W. Leslie
- Chemical Development, Pharmaceutical Technology and Development, AstraZeneca, Macclesfield Campus, SK10 2NA, Macclesfield, U.K
| | - Štefan Moravčík
- Early Chemical Development, Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, Gothenburg, SE-431 83 Mölndal, Sweden
| | - Chris D. Parsons
- Early Chemical Development, Pharmaceutical Sciences, IMED Biotech Unit, AstraZeneca, Macclesfield Campus, SK10 2NA, Macclesfield, U.K
| | - Thomas O. Ronson
- Chemical Development, Pharmaceutical Technology and Development, AstraZeneca, Macclesfield Campus, SK10 2NA, Macclesfield, U.K
| | - Rebecca E. Meadows
- Chemical Development, Pharmaceutical Technology and Development, AstraZeneca, Macclesfield Campus, SK10 2NA, Macclesfield, U.K
| |
Collapse
|